InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain
InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
CDI | Ann: SPH Notice - Aberdeen Standard Australian Small Comp Fund | 27/03/19 | 0 | 27 | |||
|
|||||||
CDI | Ann: CDI 2018 Annual Report | 22/03/19 | 0 | 33 | |||
|
|||||||
CDI | Ann: CDI Transition to Revised NZX Listing Rules | 25/02/19 | 0 | 103 | |||
|
|||||||
CDI | Ann: CDI 2019 Annual Meeting - Director Nominations | 15/02/19 | 0 | 108 | |||
|
|||||||
CDI | Ann: CDI: 2018 Full Year Results | 13/02/19 | 0 | 149 | |||
|
|||||||
CDI | Ann: SPH - Aberdeen Standard Australian Small Companies Fund | 21/09/18 | 0 | 301 | |||
|
|||||||
CDI | Ann: CDI: 2018 Interim Report | 14/09/18 | 0 | 308 | |||
|
|||||||
CDI | Ann: SPH Notice - Aberdeen Standard Investments (Asia) Limited | 06/09/18 | 0 | 241 | |||
|
See All Discussions